Cargando…
Monensin suppresses cell proliferation and invasion in ovarian cancer by enhancing MEK1 SUMOylation
Ovarian cancer is the most lethal gynecologic malignancy, and is usually diagnosed at an advanced stage. Most patients relapse within 12-24 months and die from progressive chemotherapy-resistant diseases. Significant progress has been made in developing new targeted therapies for human cancer, inclu...
Autores principales: | Yao, Shujuan, Wang, Wen, Zhou, Bin, Cui, Xiujuan, Yang, Hui, Zhang, Shiqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506924/ https://www.ncbi.nlm.nih.gov/pubmed/34650638 http://dx.doi.org/10.3892/etm.2021.10826 |
Ejemplares similares
-
Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells
por: Deng, Youlin, et al.
Publicado: (2015) -
miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met
por: Wang, Wen, et al.
Publicado: (2018) -
Combination of nigericin with cisplatin enhances the inhibitory effect of cisplatin on epithelial ovarian cancer metastasis by inhibiting slug expression via the Wnt/β-catenin signalling pathway
por: Zhou, Bin, et al.
Publicado: (2021) -
Rubidium(I) monensinate dihydrate
por: Yıldırım, Sema Öztürk, et al.
Publicado: (2007) -
LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway
por: Liu, Jian, et al.
Publicado: (2020)